Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mephenytoin
Drug ID BADD_D01386
Description Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants.
Indications and Usage For the treatment of refractory partial epilepsy.
Marketing Status approved; investigational; withdrawn
ATC Code N03AB04
DrugBank ID DB00532
KEGG ID D00375
MeSH ID D008617
PubChem ID 4060
TTD Drug ID D07RGW
NDC Product Code Not Available
UNII R420KW629U
Synonyms Mephenytoin | 5-Ethyl-3-Methyl-5-Phenylhydantoin | 5 Ethyl 3 Methyl 5 Phenylhydantoin | Mefenetoin | Methoin | Methyl Phenetoin | Phenetoin, Methyl | Phenantoin | Mesantoin
Chemical Information
Molecular Formula C12H14N2O2
CAS Registry Number 50-12-4
SMILES CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Irritability08.01.03.011; 19.04.02.013--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001---
Lymphadenopathy01.09.01.002---
Lymphoma01.12.01.001; 16.20.01.001---
Monocytosis01.02.01.004---
Nausea07.01.07.001--
Nephrotic syndrome20.05.01.002--
Nervousness19.06.02.003---
Neutropenia01.02.03.004---
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001---
Nystagmus06.05.02.006; 17.02.02.006--
Oedema08.01.07.006; 14.05.06.010---
Osteoarthritis15.01.04.001---
Pancytopenia01.03.03.003---
Photophobia06.01.01.004; 17.17.02.006--
Pulmonary fibrosis22.01.02.006--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Rash23.03.13.001---
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005---
Rash scarlatiniform23.03.13.006---
Seizure17.12.03.001--
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Tension19.06.02.005---
Thrombocytopenia01.08.01.002---
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages